Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (HALO)
NASDAQ:HALO
HALO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$37.73 - $66.00
Previous CloseN/A
Volume1.23M
Average Volume (3M)1.43M
Market Cap
$8.05B
Enterprise Value$7.11B
Total Cash (Recent Filing)$115.85M
Total Debt (Recent Filing)$1.51B
Price to Earnings (P/E)18.6
Beta1.12
Next Earnings
May 13, 2025EPS Estimate
0.96Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.43
Shares Outstanding123,533,310
10 Day Avg. Volume1,669,215
30 Day Avg. Volume1,430,316
Financial Highlights & Ratios
PEG Ratio0.29
Price to Book (P/B)N/A
Price to Sales (P/S)7.90
Price to Cash Flow (P/CF)11.20
P/FCF Ratio11.20
Enterprise Value/Market Cap0.88
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.30
Enterprise Value/Ebitda10.99
Forecast
1Y Price Target
$67.50Price Target Upside5.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
---
Halozyme News
See All HALO News
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceHALO’s 4Q24 results exceeded expectations and management reiterated previously-issued 2025 guidance.
Patent Dispute ResolutionHalozyme has approached Merck to resolve the patent issue through a license, which could lead to milestone and royalty payments.
Potential Revenue StreamsSuccessfully defending its patents could lead to potential licensing revenues from Merck, bolstering its financial position and potentially implying additional avenues of revenues from other drugs where companies are looking to develop injectable versions.
Bears Say
Intellectual Property RisksMerck has initiated proceedings with U.S. patent regulators to challenge the validity of certain Halozyme patents, arguing they are overly broad.
Patent DisputeIf Merck's challenge prevails, Halozyme might lose out on potential income and therefore raise concerns over the validity/defensibility of HALO's subQ co-formulation patents.
---
Ownership Overview
1.09% Insiders
31.16% Mutual Funds
23.94% Other Institutional Investors
12.74% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HALO FAQ
What was Halozyme Therapeutics’s price range in the past 12 months?
Halozyme Therapeutics lowest stock price was $37.73 and its highest was $66.00 in the past 12 months.
What is Halozyme Therapeutics’s market cap?
Halozyme Therapeutics’s market cap is $8.05B.
When is Halozyme Therapeutics’s upcoming earnings report date?
Halozyme Therapeutics’s upcoming earnings report date is May 13, 2025 which is in 49 days.
How were Halozyme Therapeutics’s earnings last quarter?
Halozyme Therapeutics released its earnings results on Feb 18, 2025. The company reported $1.26 earnings per share for the quarter, beating the consensus estimate of $1.158 by $0.102.
Is Halozyme Therapeutics overvalued?
According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued.
Does Halozyme Therapeutics pay dividends?
Halozyme Therapeutics does not currently pay dividends.
What is Halozyme Therapeutics’s EPS estimate?
Halozyme Therapeutics’s EPS estimate is 0.96.
How many shares outstanding does Halozyme Therapeutics have?
Halozyme Therapeutics has 123,533,310 shares outstanding.
What happened to Halozyme Therapeutics’s price movement after its last earnings report?
Halozyme Therapeutics reported an EPS of $1.26 in its last earnings report, beating expectations of $1.158. Following the earnings report the stock price went down -0.225%.
Which hedge fund is a major shareholder of Halozyme Therapeutics?
Currently, no hedge funds are holding shares in HALO
---
Halozyme Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$67.50 (5.44% Upside)
$67.50 (5.44% Upside)
Blogger Sentiment
Bullish
HALO Sentiment 92%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 161.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.73%
12-Months-Change
Fundamentals
Return on Equity
198.42%
Trailing 12-Months
Asset Growth
24.84%
Trailing 12-Months
Company Description
Halozyme Therapeutics
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
---
HALO Company Deck
---
HALO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive, with record-breaking revenue, strong growth in key products, and an optimistic outlook for 2025 and beyond. While there were some setbacks, such as the delay in Amivantamab subcutaneous approval and temporary royalty rate impacts, these were overshadowed by the overall strong financial performance and strategic achievements.Read More>---
HALO Revenue Breakdown
54.01% Royalties
36.28% Product sales
9.71% Revenues under collaborative agreements
---
HALO Stock 12 Month Forecast
Average Price Target
$67.50
▲(5.44% Upside)
Technical Analysis
Best Analysts Covering HALO
1 Year
1 Year Success Rate
20/20 ratings generated profit
1 Year Average Return
+31.64%
reiterated a buy rating 21 days ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +31.64% per trade.
---